Hemoglobin subunit beta

Also known as: Beta-globin, Hemoglobin beta chain, HBB, P68871

Hemoglobin subunit beta (beta-globin, HBB) is a globin protein that, together with alpha-globin, forms the tetrameric hemoglobin complex responsible for oxygen transport in erythrocytes. Its primary mechanism involves reversible binding of oxygen via a heme iron moiety, facilitated by cooperative conformational changes between subunits. This allosteric regulation allows efficient oxygen loading in the lungs and release in peripheral tissues, modulated by factors such as pH, carbon dioxide, and 2,3-bisphosphoglycerate. Mutations in the HBB gene can disrupt oxygen affinity or stability, leading to pathological states. Key research findings have elucidated the structural basis of hemoglobin function, including the role of specific residues in oxygen binding and cooperativity. Studies have characterized over 1,000 HBB variants, with sickle cell disease (Glu6Val) and beta-thalassemia (reduced synthesis) being the most clinically significant. Experimental research continues to explore gene therapy approaches, such as CRISPR-based editing to reactivate fetal hemoglobin or correct mutations, as well as small-molecule modulators of oxygen affinity for treating hypoxia-related conditions. Clinically, HBB is a validated therapeutic target for hemoglobinopathies. Approved treatments include hydroxyurea (to induce fetal hemoglobin) and L-glutamine (to reduce oxidative stress in sickle cell disease). Emerging therapies, such as lentiviral vector gene addition and base editing, are in clinical trials. Despite progress, challenges remain in achieving durable, safe correction of HBB mutations across diverse patient populations. For research purposes only — not medical advice.

Key data

Mechanism of action

Involved in oxygen transport from the lung to the various peripheral tissues

Research & studies

Frequently asked questions

Related peptides